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Abstract
Background: Gonadotropins are used in ovulation induction (OI) for patients with anovulatory infertility.
Pharmacologic OI is associated with risks of ovarian hyperstimulation syndrome and multiple pregnancy. Treatment
protocols that minimize these risks by promoting monofollicular development are required. A starting dose of 37.5
IU/day follitropin alfa has been used in OI, particularly among women at high risk of multifollicular development
and multiple pregnancy. A retrospective case series study was performed to evaluate rates of monofollicular
development and singleton pregnancy following standard treatment with 37.5 IU/day follitropin alfa.
Methods: Spanish centers that had performed at least five OI cycles during 2008 using 37.5 IU/day follitropin alfa
as a starting dose were invited to participate. Data could be provided from any cycle performed in 2008 (up to a
maximum of 12 consecutive cycles per site). Case report forms were collected during April-November 2009 and
reviewed centrally. Descriptive statistics were obtained from all cases, and follicular development and clinical
pregnancy rates assessed. Potential associations of age and body mass index with follicular development and
clinical pregnancy were assessed using univariate correlation analyses.
Results: Thirty centers provided data on 316 cycles of OI using a starting dose of 37.5 IU/day follitropin alfa.
Polycystic ovary syndrome was the cause of anovulatory infertility in 217 (68.7%) cases. Follitropin alfa at 37.5 IU/
day was sufficient to achieve ovarian stimulation in 230 (72.8%) cycles. A single follicle ≥16 mm in diameter
developed in 193 cycles (61.1%; 95% confidence interval [CI] 55.7-66.4%). Seventy-eight women (24.7%; 95% CI
19.9-29.5%) became pregnant: 94.9% singleton and 5.1% twin pregnancies. Fourteen started cycles (4.4%) were
cancelled, mainly due to poor response. Univariate correlation analyses detected weak associations.
Conclusions: Monofollicular growth rate was comparable with optimal rates reported elsewhere and the
pregnancy rate exceeded that in other studies of OI using gonadotropins. A starting dose of 37.5 IU/day follitropin
alfa is an effective option in selected cases to prevent ovarian hyper-response without loss of efficacy. The analysis
could not identify a single selection criterion for individuals who would benefit from this treatment approach; this
merits further investigation in prospective studies.
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Background
Exogenous follicle-stimulating hormone (FSH) is the
most common treatment for chronic anovulatory inferti-
lity. Pharmacologic ovulation induction (OI) results in a
pregnancy rate of 10-20% per cycle [1]. However, treat-
ment with exogenous gonadotropins carries a risk of
multifollicular development, leading to multiple preg-
nancy in 5-20% of cycles. A 50% increase in twin birth
rates has been observed over the last three decades, and
high-order multiple birth rates have increased even
more dramatically. This is linked to the increased use of
gonadotropins to induce ovulation [1,2]. Furthermore,
precautionary cancellation of cycles may be required
when more than three follicles ≥16 mm in diameter
develop [3,4]. Indeed, 5-10% of started cycles are * Correspondence: ibrunacat@gmail.com
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(OHSS) [5-9].
Various therapeutic strategies have been attempted to
limit the growth and development of multiple preovula-
tory ovarian follicles [6,7,10-12]. Efforts have been made
to modulate ovarian response to gonadotropins by con-
current treatment with anti-estrogens, aromatase inhibi-
tors, and gonadotropin-releasing hormone analogs to
reduce the dose of gonadotropin required [12-14], and
by directly lowering the standard doses of gonadotropins
administered [15-17]. These approaches have had lim-
ited success and multiple follicular development, multi-
ple pregnancy, and OHSS still remain as major,
unresolved issues in OI.
In recent years, interest has been growing in the use
of ultra-low-dose FSH regimens in OI for women with
polycystic ovary syndrome (PCOS). In one study in
PCOS, OI using a chronic low-dose FSH regimen
resulted in a low multiple (twin) pregnancy rate (5%)
and no reported cases of OHSS without compromising
the clinical pregnancy rate (29% per started cycle) [18].
By contrast, a conventional treatment protocol resulted
in a multiple pregnancy rate of almost 36% and a severe
OHSS rate of 4.6% [19].
Ovarian stimulation with low-dose gonadotropins is
based on the concept of the ‘FSH threshold’ proposed
many years ago by Brown, who suggested that a thresh-
old level of FSH must be reached to achieve follicular
development [20]. A slight elevation in plasma FSH con-
centration (10-30% above the threshold) is sufficient to
stimulate normal follicular development, whereas further
elevation may cause hyper-stimulation.
Conventional OI regimens use supraphysiological doses
of FSH, whereas low-dose regimens aim to develop an
initial cohort of follicles without exceeding the FSH
threshold. Low-dose protocols usually involve adminis-
tration of a starting dose of 50-75 IU FSH for 7-14 days;
if necessary, the dose is increased by 50% until follicular
development begins [21]. Once a dominant follicle is
identified, FSH treatment is maintained until the criteria
for human chorionic gonadotropin (hCG) administration
are fulfilled. Ovulation is reported to be achieved in
approximately 70% of low-dose FSH treatment cycles
[22-24]. However, a recent consensus statement con-
cluded that, although low-dose FSH is effective in OI for
women with PCOS, further refinements to treatment
protocols are required to optimize outcomes [25].
Clinicians understand that the use of gentler stimula-
tion regimens could reduce the incidence of high-order
multiple pregnancy, but would increase the rate of cycle
cancellation due to poor ovarian response and reduce
pregnancy rates (with the associated human and finan-
cial cost implications). Nevertheless, practitioners do
identify individuals who are at particular risk of multiple
pregnancy. For these patients, the use of ultra-low-doses
(37.5 IU/day) of follitropin alfa, a recombinant FSH, is
considered to be a safer approach for achieving preg-
nancy while limiting the chance of multiple pregnancy.
Because of the sporadic nature of this clinical practice,
no formal study has been published. Therefore, the out-
comes remain unknown, filed only in the archives of
individual medical centers. In this pilot study, we col-
lected existing single case records to create a case series.
T h em a i na i mo ft h es t u d yw a st od e t e r m i n et h er a t eo f
monofollicular development with a starting dose of 37.5
IU/day follitropin alfa in OI. Additionally, patient char-
acteristics, the total dose of follitropin alfa required, and
rates of singleton and multiple pregnancy and cycle can-
cellation were evaluated. The results of this study may
provide the basis for a follow-up, prospective clinical
trial.
Methods
Case series and scope
T h i sr e t r o s p e c t i v ec a s es e r ies study was based on data
from case reports of women with anovulatory infertility
(mainly due to PCOS) who were treated with follitropin
alfa (GONAL-f
®, Merck Serono S.A. - Geneva, Switzer-
land, a branch of Merck Serono S.A., Coinsins, Switzer-
land, an affiliate of Merck KGaA, Darmstadt, Germany)
a tas t a r t i n gd o s eo f3 7 . 5I U / d a yt oi n d u c eo v u l a t i o n
according to standard practice criteria. Any Spanish
infertility center that had conducted at least five such OI
cycles during 2008 was eligible to participate. In order to
standardize and balance participation, data from a maxi-
mum of 12 consecutive cases were allowed per site. The
study was restricted to cycles of OI conducted during
2008 (although cycles performed up to April 1, 2009
were considered as conducted in the previous year).
Data collection
Case report forms (CRFs) were provided to centers willing
to participate and able to provide at least five suitable case
reports. Each CRF included sections relating to baseline
characteristics, infertility history, follitropin alfa dosage,
duration of ovarian stimulation, follicular development,
and the number of gestational sacs. Participants completed
CRFs with data obtained directly from medical records. As
data were coded and dissociated from any personal identi-
fier, neither ethics committee approval nor informed con-
sent was required. Completed CRFs were collected
between April and November 2009. Data were reviewed
centrally and inconsistencies were resolved before the
database was locked on December 20, 2009.
Outcomes
The primary outcome was the monofollicular develop-
ment rate, defined as the growth of a single follicle ≥16
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Other outcomes included clinical pregnancy rate at ≥7
weeks gestation and number of gestational sacs (as iden-
tified by ultrasound), cycle cancellation rate (with rele-
vant reason), duration of ovarian stimulation, and total
dose of follitropin alfa required.
Data analysis
Descriptive statistics of the study population are pre-
sented as mean values with standard deviations for con-
tinuous variables and as frequency and percentages for
discrete variables. Associated 95% confidence intervals
(CI) are provided for the two main variables. Rates were
obtained directly as the quotient of the two relevant
variables.
The study population was further classified based on
age (≤35 or > 35 years) and body mass index (BMI; ≤25
kg/m
2 or > 25 kg/m
2). Differences between these pairs
of subgroups were analyzed using the Student’s t-test,
Mann-Whitney U test or Fisher Exact test, as appropri-
ate. Potential associations between follicular develop-
ment and clinical pregnancy and age, BMI, and total
dose of follitropin alfa were assessed through univariate
correlation analysis.
Data were evaluated and statistical analyses performed
using SPSS (Statistical Package for the Social Sciences).
Results
Thirty participating centers provided data on 316 cycles
in which women received a starting dose of 37.5 IU/day
follitropin alfa for OI. This represents 4.4% of the 7176
OI cycles undertaken in these centers within the study
period.
Baseline characteristics of the study population are
presented in Table 1. The mean age of women in this
study was 31.8 years, and the majority of women (262;
82.9%) were ≤35 years of age. Although the duration of
infertility was relatively long, exposure to OI treatment
was limited, with a mean of only 1.2 previous cycles.
PCOS was the cause of anovulatory infertility in more
than two-thirds of cases (217; 68.7%). The majority of
women (217; 68.7%) had a mean BMI within the normal
range (≤25 kg/m
2; the upper limit of established normal
range). Overall, the study population comprised young,
slim women with a long history of infertility due to
PCOS, but minimal prior exposure to gonadotropins.
A starting dose of 37.5 IU/day follitropin alfa was suf-
ficient to achieve ovarian stimulation in 230 (72.8%)
cycles, while the remainder (86; 27.2%) required only
small incremental dose increases (as reflected by a mean
final daily dose of 49.9 IU). The mean duration of ovar-
ian stimulation was 11.0 days and a mean total dose of
517 IU follitropin alfa was required. A single follicle ≥16
mm in diameter developed in the majority of cycles
(61.1%; 95% CI 55.7-66.4%) and the pooled rate of
mono- or bifollicular development approached 90%. The
cancellation rate was 4.4%, and was mainly due to a
poor ovarian response. Clinical pregnancy was achieved
in 24.7% (95% CI 19.9-29.5%) of started cycles. Most
pregnancies were singletons (94.9%); only four twin
pregnancies occurred and there were no high-order
multiple pregnancies.
Outcomes among women aged ≤35 years and those
aged > 35 years were compared, as a cut-off of 35 years
is generally agreed to designate advanced reproductive
age for assisted reproduction purposes. As shown in
Table 2, there was a difference in mean age of 6.4 years
between the subgroups (30.7 vs 37.1 years; p = 0.0001).
The only other significant difference between subgroups
was that the mean number of previous OI cycles in the
Table 1 All cases: baseline characteristics, ovarian
stimulation, and OI outcome
Characteristic/variable All cases (n = 316)
Age, years 31.8 (3.6)
BMI, kg/m
2 23.7 (4.2)
Etiology
PCOS, n (%) 217 (68.7)
Other/unknown, n (%) 99 (31.3)
Infertility characteristics
Duration of infertility, months 27.8 (18.6)
Number of previous OI cycles 1.2 (1.2)
Ovarian stimulation
Starting daily dose, IU 37.5 (0.0)
Cycles that completed at 37.5 IU, n (%) 230 (72.8)
Cycles that required a dose increase, n (%) 86 (27.2)
Final daily dose, IU 49.9 (24.1)
Total dose of r-hFSH, IU 517 (410)
Duration of stimulation, days 11.0 (5.1)
Cycles cancelled, n (%) 14 (4.4)
Poor response, n (%) 10 (3.0)
Risk of OHSS, n (%) 4 (1.3)
Follicular development
Number of follicles ≥16 mm in diameter 1.4 (0.7)
Cycles resulting in 0 follicles, n (%) 9 (2.8)
Cycles resulting in 1 follicle, n (%) 193 (61.1)
Cycles resulting in 2 follicles, n (%) 84 (26.6)
Cycles resulting in ≥3 follicles, n (%) 29 (9.2)
Cycles with no data, n (%) 1 (0.3)
OI outcome
Clinical pregnancy, * n (%) 78 (24.7)
Singleton pregnancy, n (%) 74 (94.9)
Twin pregnancy, n (%) 4 (5.1)
Values are mean (SD) unless otherwise indicated.
*Defined as gestation ≥7 weeks.
BMI, body mass index; OHSS, ovarian hyperstimulation syndrome; OI,
ovulation induction; PCOS, polycystic ovary syndrome; r-hFSH, recombinant
human follicle-stimulating hormone; SD, standard deviation.
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group (1.9 vs 0.8; p = 0.02). A trend toward an increased
pregnancy rate was also observed in the younger versus
the older subgroup, despite a higher cycle cancellation
rate. In addition, the four cycles that were cancelled
because of a risk of OHSS, as well as the four twin preg-
nancies, all occurred in the subgroup of women aged
≤35 years.
Outcomes among women with a BMI of ≤25 kg/m
2
and > 25 kg/m
2 were also compared, as being over-
weight negatively affects the ovarian response to OI. A
significant difference of 7.5 kg/m
2 in mean BMI score
was found between the BMI ≤25 kg/m
2 and > 25 kg/m
2
subgroups (p = 0.0001; Table 3). This difference
reflected a mean difference of 19 kg in body weight. As
expected, most of the cases (89%) in the BMI > 25 kg/
m
2 subgroup presented with PCOS versus 60% of cases
in the BMI ≤25 kg/m
2 subgroup (p = 0.0001). Ovarian
resistance to stimulation is well recognized in women
with excess body weight. This effect resulted in a signifi-
cantly longer mean duration of stimulation (2.1 days; p
= 0.001) and a higher mean follitropin alfa requirement
(32 IU per cycle; p = 0.005) in the high versus low BMI
subgroup. All other variables were similar in both sub-
groups, although the pregnancy rate was slightly higher
(24.9% vs 20.7%) in the low versus high BMI subgroup.
Univariate correlation analyses were used to identify
potential associations between follicles ≥16 mm in dia-
meter or clinical pregnancy with age, BMI, or total dose
of follitropin alfa. Weak positive associations were found
between all pairs of variables analyzed; however, none
were statistically significant.
Discussion
The aim of this case series study was to evaluate the
effectiveness of 37.5 IU/day follitropin alfa as a starting
dose in OI for women with anovulatory infertility. No
data on this therapeutic approach were previously avail-
able. Because of the reduced risk of ovarian hyper-
response associated with this low dose, we conducted a
case series study from existing single case reports. We
showed that the use of 37.5 IU/day follitropin alfa can
prevent multifollicular growth among women at risk of
ovarian hyper-response and multiple pregnancy.
This ultra-low-dose approach (37.5 IU/day follitropin
alfa) led to the development of a single follicle ≥16 mm
in diameter in 61.1% and clinical pregnancy in 24.7% of
started cycles. Indeed, rates of both monofollicular
development and clinical pregnancy are higher than
those reported in OI using a standard daily dose of 75
IU FSH. The total dose of follitropin alfa required was
517 IU and mean duration of ovarian stimulation was
11.0 days, indicating that minimal dose adjustment was
needed. Notably, despite the ultra-low-dose regimen,
only 14 (4.4%) cycles were cancelled and almost all were
due to poor ovarian response. Only 4 (1.3%) cycles were
cancelled because of a risk of OHSS (based on the num-
ber of follicles on ultrasound), thus fulfilling a major
goal in OI. Both the lower total dose of follitropin alfa
required and the reduction in risk of OHSS could
improve the patients’ experience of OI.
Data from a recently published large, prospective,
observational study provide a broad representation of
the use of recombinant human FSH (r-hFSH) in OI in
French clinical practice (n = 1398) [26]. Most patients
Table 2 Subgroup analysis of women aged ≤35 years versus > 35 years
Characteristic/variable ≤35 years (n = 262) > 35 years (n = 54) p value
Age, years 30.7 (2.9) 37.1 (1.1) 0.0001
BMI, kg/m
2 23.5 (4.7) 24.6 (3.6) NS
PCOS, n (%) 182 (69.5) 35 (64.8) NS
Other/unknown etiology, n (%) 80 (30.5) 19 (35.2) NS
Duration of infertility, months 27.6 (17.9) 27.8 (21.0) NS
Number of previous OI cycles 1.9 (1.3) 0.8 (0.8) 0.02
Duration of stimulation, days 11.1 (5.2) 10.6 (4.9) NS
Total dose of r-hFSH, IU 525 (425) 486 (333) NS
Cycles cancelled, n (%) 13 (5.0) 1 (1.9) NS
Poor response, n (%) 9 (3.4) 1 (1.9) NS
OHSS risk, n (%) 4 (1.5) 0 (0) NS
Number of follicles ≥16 mm in diameter 1.3 (0.6) 1.5 (0.7) NS
Clinical pregnancy, * n (%) 67 (25.6) 11 (20.4) NS
Singleton pregnancy, n (%) 63 (94.0) 11 (100) NS
Twin pregnancy, n (%) 4 (6.0) 0 (0) NS
Values are mean (SD) unless otherwise indicated.
*Defined as gestation ≥7 weeks.
BMI, body mass index; NS, not significant; OHSS, ovarian hyperstimulation syndrome; OI, ovulation induction; PCOS, polycystic ovary syndrome; r-hFSH,
recombinant human follicle-stimulating hormone; SD, standard deviation.
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tory infertility and, of these, 35% had a diagnosis of
PCOS. A starting dose of 75 IU/day r-hFSH, without
adjustment, stimulated the development of 1.3 ± 1.5 fol-
licles ≥15 mm in diameter. The clinical pregnancy rate
was 18% per started cycle; 16% of these were multiple
pregnancies (14% twins and 2% high-order multiple
pregnancies). The cycle cancellation rate was 11%, and
was mainly due to ovarian hyper-response. The rates of
multiple pregnancy and cycle cancellation due to hyper-
response indicate that there is still scope for improve-
ment in OI treatment protocols, and supports the search
for milder treatment strategies to optimize outcomes.
The use of low gonadotropin doses to induce the
maturation of a single preovulatory follicle seems to
represent the most realistic therapeutic approach to OI
at present. A starting dose of 50 IU/day r-hFSH was
evaluated in a large, observational study in OI in 88
Spanish clinics [17]. Data were included on 343 women
with anovulatory infertility, of whom two-thirds (231;
67%) had ultrasound evidence of PCOS. Of 945 cycles
started, 817 cycles were completed, resulting in a 14%
cancellation rate (due to spontaneous ovulation or ovar-
ian hyper-response). The monofollicular development
rate was 53% (501/945) per started cycle. A total of 136
clinical pregnancies occurred (14% per started cycle),
with eight twin and no high-order multiple pregnancies.
Sixty-four (6.8%) cases of OHSS were recorded but
none required hospitalization. The median daily dose of
r-hFSH in all cycles was the starting dose of 50 IU. This
study supports the use of 50 IU/day r-hFSH in OI for
anovulatory infertility and the possibility of even lower
doses for some patients.
Two low-dose, step-up FSH regimens for OI were
compared in a trial at 18 European and Canadian cen-
ters [11]. Patients with WHO Group II anovulatory
infertility (n = 158) received 50 IU/day r-hFSH for 7
days and then the daily dose was increased by incre-
ments of 25 or 50 IU r-hFSH per week. The monofolli-
cular development rate in the lower dose group was
almost twice that of the higher dose group (41% vs 22%,
respectively). The ongoing pregnancy rate was 20% and
13% in the 25 IU and 50 IU dose groups, respectively.
The cancellation rate due to ovarian hyper-response was
fourfold greater in the higher versus lower dose group
(21% vs 5%, respectively), whereas the cancellation rate
due to poor ovarian response was 5% in both groups.
The ability to accurately predict the FSH threshold
would, theoretically, enable clinicians to prescribe the
lowest effective dose to induce monofollicular develop-
ment for each individual patient. Eight variables were
f o u n dt ob ep r e d i c t i v eo ft he FSH threshold dose in OI
in a multivariate analysis of data for women with anovu-
latory infertility [27]. Three variables (BMI, spontaneous
menstrual cycle history, and ovarian volume) were
found to be significant, independent predictors of the
FSH threshold dose, and a simple nomogram based on
these predictive factors was constructed. The daily doses
used in this step-up protocol ranged from 75 to 187.5
IU FSH and were, therefore, higher than the starting
daily dose of 37.5 IU evaluated in the current case series
study.
Table 3 Subgroup analysis of women with BMI ≤25 kg/m
2 vs > 25 kg/m
2
Characteristic/variable ≤25 kg/m
2 (n = 217) > 25 kg/m
2 (n = 91) p value
Age, years 31.6 (3.69) 32.3 (3.7) NS
BMI, kg/m
2 21.5 (2.1) 29.0 (3.3) 0.0001
PCOS, n (%) 131 (60.4) 81 (89.0) 0.0001
Other/unknown etiology, n (%) 84 (38.7) 10 (11.0) 0.0001
Duration of infertility, months 29.0 (3.3) 28.0 (18.8) NS
Number of previous OI cycles 1.2 (1.2) 1.2 (1.2) NS
Duration of stimulation, days 10.4 (5.5) 12.5 (4.0) 0.001
Total dose of r-hFSH, IU 574 (417) 606 (356) 0.005
Cycles cancelled, n (%) 11 (5.1) 3 (3.3) NS
Poor response, n (%) 8 (3.7) 2 (2.2) NS
OHSS risk, n (%) 3 (1.4) 1 (1.1) NS
Number of follicles ≥16 mm in diameter 1.4 (0.6) 1.4 (0.3) NS
Clinical pregnancy, * n (%) 54 (24.9) 19 (20.7) NS
Singleton pregnancy, n (%) 52 (96.3) 17 (89.5) NS
Twin pregnancy, n (%) 2 (3.7) 2 (10.5) NS
BMI data not recorded in eight cases, so n = 308.
Values are mean (SD) unless otherwise indicated.
*Defined as gestation ≥7 weeks.
BMI, body mass index; NS, not significant; OHSS, ovarian hyperstimulation syndrome; OI, ovulation induction; PCOS, polycystic ovary syndrome; r-hFSH,
recombinant human follicle-stimulating hormone; SD, standard deviation.
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study used criteria to identify cases suitable for an ultra-
low-dose follitropin alfa regimen, our analysis of data
from this case series failed to identify single variables
that were associated with a monofollicular response.
Therefore, we were unable to identify women who
would be most likely to benefit from this therapeutic
approach. The complexity of the criteria and the cir-
cumstances that clinicians take into account when
choosing treatment protocols could not be captured in
this study, and requires further investigation.
We acknowledge that observational studies, such as
this case series, have a number of limitations. Our study
was uncontrolled, there was a potential risk of bias in
the selection and reporting of cases, and data collection
ultimately depended on the availability and accuracy of
medical records. For example, data on live births would
have been useful but were not readily available from
infertility center records. However, efforts were made to
address these issues and ensure that valid information
was obtained. For example, a short set of universally
available data were collected from each case to minimize
any site-related discrepancies in standard practice. In
addition, no fewer than five and no more than 12 conse-
cutive case reports were provided by each center.
Furthermore, the study window was limited to a single
year (2008) to minimize potential changes in practice.
Thus, we believe that our findings provide valuable
information on the use of follitropin alfa at a starting
dose of 37.5 IU in OI.
The results of this case series study support the use of
ultra-low-dose follitropin alfa (37.5 IU/day) in OI for
women with anovulatory infertility. Infertile women who
wish to become pregnant often overlook the risks of
multiple pregnancy or OHSS. Experienced clinicians can
effectively advise individuals who are at particularly high
risk of OHSS on the use of low-dose therapy to maxi-
mize the likelihood of pregnancy while avoiding high-
order multiple pregnancy. The potential benefits of
ultra-low-dose follitropin alfa treatment (37.5 IU/day)
merits further investigation in prospective studies to
identify patients who could gain the greatest benefit
from this therapeutic approach.
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